Featured Research

from universities, journals, and other organizations

Stroke risk higher after shingles, but antiviral drugs may provide protection

Date:
April 3, 2014
Source:
Oxford University Press (OUP)
Summary:
Patients’ risk of stroke significantly increased following the first signs of shingles, but antiviral drugs appeared to offer some protection, according to a new study. People with shingles, an often painful skin rash caused by the same virus that causes chickenpox, had a higher stroke risk in the first 6 months after shingles symptoms appeared; this risk was particularly increased in patients with a rash near their eyes, the study found.

Patients’ risk of stroke significantly increased following the first signs of shingles, but antiviral drugs appeared to offer some protection, according to a new study in Clinical Infectious Diseases, now available online. People with shingles, an often painful skin rash caused by the same virus that causes chickenpox, had a higher stroke risk in the first 6 months after shingles symptoms appeared; this risk was particularly increased in patients with a rash near their eyes, the study found.

Shingles, or herpes zoster, is a significant public health problem, affecting an estimated 1 million adults in the U.S. and nearly 90,000 in the U.K. each year.

The disease develops when the varicella-zoster virus, which causes chickenpox in children and then remains dormant in the body, reactivates later in life. Sinιad Langan, MD, PhD, and colleagues at the London School of Hygiene & Tropical Medicine identified patients with first-ever incidents of shingles and stroke, and also examined antiviral treatment records for shingles, drawing from a database of information from patients across 600 general practices in the U.K.

Researchers compared the risk of stroke in the time period after the patient had shingles to time periods when the patient did not have recent shingles. Among the 6,584 patients included in the study, the stroke rate was 63 percent higher in the first four weeks after a shingles episode compared to the patient’s baseline risk, diminishing slowly up to 6 months later. The stroke risk increased up to three-fold for a short period of time among those with a shingles rash affecting the skin around their eyes, compared to baseline risk. 

In patients treated with oral antiviral medication for their shingles—55 percent of study participants—the risk of stroke was lower than in those not treated with antivirals. “The relatively low prescribing rates of antiviral therapy in U.K. general practice after developing shingles need to be improved,” Dr. Langan said, “as our study suggests that stroke risks following shingles are lower in those treated with oral antiviral therapy compared to individuals not treated with antiviral therapy.”The findings also highlight the importance of vaccinating older adults against shingles, which can reduce the risk of developing the painful condition in the first place. A shingles vaccine is available and recommended for adults over 60 in the U.S. and for those in their 70s in the U.K.

In a related editorial, Maria A. Nagel, MD, and Donald H. Gilden, MD, of the University of Colorado School of Medicine, noted that the findings confirm previous studies of shingles and stroke risk from Taiwan, Denmark, and the U.K. This latest study is “the first to show that the increased risk of stroke after zoster can be reduced with antiviral treatment,” they wrote. 


Story Source:

The above story is based on materials provided by Oxford University Press (OUP). Note: Materials may be edited for content and length.


Journal References:

  1. S. M. Langan, C. Minassian, L. Smeeth, S. L. Thomas. Risk of Stroke Following Herpes Zoster: A Self-Controlled Case-Series Study. Clinical Infectious Diseases, 2014; DOI: 10.1093/cid/ciu098
  2. M. Nagel, D. Gilden. Varicella Zoster Virus Infection: Generally Benign in Kids, Bad in Grown-ups. Clinical Infectious Diseases, 2014; DOI: 10.1093/cid/ciu099

Cite This Page:

Oxford University Press (OUP). "Stroke risk higher after shingles, but antiviral drugs may provide protection." ScienceDaily. ScienceDaily, 3 April 2014. <www.sciencedaily.com/releases/2014/04/140403084353.htm>.
Oxford University Press (OUP). (2014, April 3). Stroke risk higher after shingles, but antiviral drugs may provide protection. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/04/140403084353.htm
Oxford University Press (OUP). "Stroke risk higher after shingles, but antiviral drugs may provide protection." ScienceDaily. www.sciencedaily.com/releases/2014/04/140403084353.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins